According to Aprea Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.01085. At the end of 2022 the company had a P/E ratio of -0.0680.
Year | P/E ratio | Change |
---|---|---|
2022 | -0.0680 | -95.85% |
2021 | -1.64 | -15.33% |
2020 | -1.94 | -93.73% |
2019 | -30.9 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
Magellan Health
MGLN | N/A | N/A | ๐บ๐ธ USA |
Amedisys AMED | 950 | -94,030.85% | ๐บ๐ธ USA |
Healthcare Services Group HCSG | 26.6 | -2,735.05% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.